Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.

Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH

At an AJMC Stakeholder Interchange in Houston, leukemia specialists from academic centers and community practices said menin inhibitors work best in combination, warned that differentiation syndrome can strike months into therapy, and described payer rules that delay access even at flagship centers.

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.

At an AJMC® Stakeholder Interchange in New York, New York, leukemia specialists agreed that menin inhibitors fill a real gap in relapsed/refractory acute myeloid leukemia, but said that slow molecular testing, formulary rules, and thin community infrastructure still determine which patients get them and how fast.

Deep learning digital pathology predicts mantle cell lymphoma outcomes from routine biopsy slides, matching biomarkers to improve MIPI risk stratification.